Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Tirzepatide is the active ingredient in the injectable medications Mounjaro and Zepbound
The market for these drugs is projected to hit $66.48 billion in a single year and is on track to reach a staggering $879.9 billion by 2034
Surprisingly, tirzepatide shows slightly lower rates of nausea (30-37% vs 44%) and vomiting (9-17% vs 24%) in clinical trials despite being more potent
We also examine coverage in other state regulated insurance markets: the small group market, state employee plans, and Medicaid to see whether there is evidence of emerging regional patterns in coverage of GLP-1s
Rapid weight loss on GLP-1 drugs does not discriminate between fat and lean tissue
PMID: 40754386
US$ 26.72
US$ 26.06
US$ 29.80
US$ 23.78
US$ 25.12
US$ 23.98
US$ 28.42
US$ 24.90
US$ 20.18
US$ 20.00
US$ 25.36
US$ 21.86
US$ 26.29
US$ 20.55
